GVHD remains a major problem in allo-SCT. We explored the presence of APC in skin biopsies of GVHD patients, using the IgG receptor CD64 expression as a hallmark for activated APC. By immunohistochemistry we demonstrated CD64 to be upregulated on host APC in skin biopsies of patients with acute GVHD and, less prominently, in chronic GVHD. Double staining for CD32 polymorphism revealed CD64-positive cells to be mainly of host origin. The majority of CD64-positive cells coexpressed CD68, indicating a macrophage phenotype. Given its very restricted cellular distribution, CD64 may represent an excellent target for APC-directed therapies in GVHD.
Introduction
GVHD is still a major drawback in allo-SCT. Therapeutic strategies in GVHD frequently aim at T-cell suppression, although that several animal studies point at a role for APC in induction and maintenance of GVHD. [1] [2] [3] [4] [5] [6] Hence, selective targeting of activated APC might be beneficial in the treatment of GVHD. In search for strategies to intervene with activated APC, the high-affinity IgG receptor CD64 (FcgRI) emerges as a therapeutic target. Its presence is restricted to mono-myelocytic cells, and the receptor is profoundly upregulated by proinflammatory cytokines. [7] [8] [9] We analyzed skin biopsies of patients with GVHD for expression of CD64, and determined the origin of CD64-positive cells by different techniques. CD64 was found to be upregulated in acute GVHD on APC of host origin.
Patients and methods

Patients
After informed consent, a pre-SCT skin biopsy was taken from all patients undergoing allo-SCT for hematological malignancies at the University Medical Center Utrecht, during anesthesia for insertion of an i.v. catheter. Patients received a conditioning regimen according to EBMT guidelines, including CsA and MTX as GVHD prophylaxis. Post-SCT biopsies were only taken in case of acute GVHD, diagnosed clinically according to the Glu¨cksberg criteria, and before start of GVHD treatment. 10 Standard histopathological features of GVHD were used for a definite diagnosis. 11 The study was approved by the Medical Ethics Committee of the University Medical Center Utrecht. mAb FITC-labeled and unlabeled CD64 (mAb, mouse (m)IgG1) 10.1; Serotec, Oxford, UK), CD1a mAb (M 0721, mIgG2a; Dako, Glostrup, Denmark) and CD68mAb (M0718, mIgG1; Dako) were used for detection of Langerhans cells and macrophages, respectively. For immuno-hybrid double staining CD64 (ITK Diagnostics, Uithoorn, The Netherlands) and CD3mAb (Lei-4; Becton Dickinson, San Jose, CA, USA) were used. Murine mAb 41H16 (mIgG2a; a kind gift from Dr B Longenecker (Edmonton, Canada) and MDE-9 (human (h)IgG1 (Medarex, Annandale, NJ, USA) were used for the detection of FcgRIIa-H131. 12, 13 PCR genotyping FcgRIIa genotyping of patients and donors was performed on genomic DNA isolated by QIAamp DNA Blood Minikits (Qiagen, Valencia, CA, USA), using PCR.
PCR-based genotyping as described. 14 DNA samples from FcgRIIa-R/R131, IIa-R/H131 and IIa-H/H131 individuals, allotyped by sequencing the CD32 gene, were always included as internal controls.
Immunohistochemistry CD64 single-staining. A measure of 6 mm sections of pre-and post-SCT skin biopsies were incubated with FITC-conjugated CD64 Ab 10.1 (60 min), subsequently with alkaline phosphatase (AP)-conjugated sheep F(ab) anti-FITC (Boehringer Mannheim, Mannheim, Germany). AP activity was demonstrated using Vector Red Alkaline Phosphatase Substrate Kit I (Vector Laboratories, Burlingame, CA, USA), with additional levamisole (Vector) to inhibit endogenous AP activity. Slides were lightly counterstained with hematoxylin.
CD64 double-staining. Slides were incubated with CD68mAb (Dako), or anti-CD1a mAb (Dako), followed by biotinylated horse anti-mouse antibodies (Vector). Subsequently, slides were incubated with FITC-conjugated CD64 10.1 mAb and with peroxidase (PO)-conjugated streptavidine ABC complex (Boehringer) and AP-conjugated sheep anti-FITC (F(ab) fragments (Boehringer). Incubation with blue AP-substrate (Vector Blue Alkaline Phosphatase Substrate Kit III) complemented with levamisole, for 20 min, was followed by incubation with AEC substrate (AEC Chromogen Kit, Sigma, St Louis, NO, USA), resulting in a red staining.
CD32 double staining was performed on FcgRIIA-131 donor/host mismatches, by incubating with CD64mAb 10.1, followed by biotinylated horse anti-mouse (Boehringer) Ab. Then either FITC-labeled MDE-9 or FITClabeled 41H16 was added, followed by AP-conjugated sheep anti-fluorescine and PO-conjugated streptavidine.
Immuno-hybrid double staining. Paraffin sections were deparaffinized, rehydrated, blocked for endogeneous peroxidase activity using methanol/hydrogen peroxide mixture. After boiling in sodium citrate buffer (pH 6.0), 25 ml of hybridization mixture was applied. Plasmids for X (DXZ) and Y (SRY) chromosomes were digoxigenin 11 d 0 UTP labeled using the nick-translation kit (Roche, Mannheim, Germany). Probe hybrids were detected using FITC-labeled sheep anti-Dig in phosphate-buffered saline supplemented with 10% normal sheep serum. Subsequently, slides were incubated with mouse anti-human CD68 (ITK Diagnostics). Rabbit anti-mouse horseradish peroxidase (Dako) was used for detection. Peroxidase activity was detected using 1/50 diluted Tyramide-TRITC (PerkinElmer, Boston, MA, USA) in amplification diluents. Nuclei were counterstained with diluted DAPI in phosphate-buffered saline. (Table 1) . Two patients with acute GVHD were mismatched for FcgRIIa at amino acid position 131 with their respective donors. Three patients were eligible for donor/host gender mismatch studies. Compared with CD64 expression in their pre-SCT biopsies, skin biopsies of all patients with acute GVHD showed a markedly increased number of CD64-positive cells. A relatively small increase was observed in the two chronic GVHD biopsies. An example of CD64 staining of skin biopsies before GVHD, and during chronic and acute GVHD is shown in Figure 1 . CD3-positive cells were present, mostly adjacent to CD64-positive cells (data not shown).
Results
Patients
CD64 double-staining. To determine, whether CD64-positive cells were of DC or macrophage phenotype, immuno histochemical double staining was performed, using CD1a and CD68mAb, respectively. CD64-expressing cells costained with CD68, but not with CD1a. In two FcgRIIa-mismatched patients CD64-positive cells were positive for MDE-9 (referring to the patient's genotype FcgRIIA-H/H131), but not for 41H16, indicating CD64-positive cells to be of host origin (Figure 2a ). Double staining with 41H16 and CD3 indicated T-cells to be from donor origin (n ¼ 2, data not shown). In contrast, CD64-positive cells of the FcgRIIA-R/R131 genotype costained with mAb 41H16, again demonstrating CD64-positive cells to be mainly of host origin.
We next employed X and Y chromosome FISH techniques. Paraffin slides of gender-mismatched donor/ host paired biopsies were studied with FISH techniques combined with CD68 immunohistochemical staining, as CD64 staining is not effective in this procedure. In skin biopsies of a male patient with a female donor (n ¼ 2) CD68-positive cells were observed to be positive for the Y chromosome, confirming these cells to be of host origin (Figure 2b ).
Discussion
In this study, we documented a strong expression of CD64-positive cells, being a marker for activated APC, in skin biopsies of patients with acute GVHD. CD64 expression was found to be less prominent in patients with chronic GVHD, although still increased, compared with pre-SCT biopsies of these patients. CD64-positive cells exhibited a macrophage phenotype and appeared to be mainly of host origin. CD3-positive cells were shown to be preponderantly of donor origin. Because of medical ethical reasons, we had no serial biopsies without the clinical suspicion of acute GVHD. We, thus, cannot state that CD64 upregulation is pathognomonic for acute GVHD. Increased CD64 expression may already be present during or after the conditioning regimen or after stem cell reinfusion without causing disease. For the same reasons, negative control biopsies of non-GVHD patients could not be obtained. However, in one patient with a skin rash, the suspected diagnosis of acute GVHD was not confirmed by standardized immunohistochemical diagnostics (data not shown). This particular skin biopsy showed no increase in CD64-positive cells, suggesting CD64 to indeed represent a marker for acute GVHD.
CD64, expressed by activated APC, may represent a suitable target for immunotherapy, as already documented in studies of chronic inflammation. 15 In murine models of chronic dermatitis, selective apoptosis of CD64-positive cells by a CD64-targeting immunotoxin decreased T-cell recruitment and activity. Ex vivo CD64-immunotoxininduced apoptosis of activated macrophages present in synovial fluids of rheumatoid arthritis patients, and led to reduction of proinflammatory cytokines. 15, 16 Based on these data, CD64-directed interventions might be of additional value for treatment of GVHD, particularly acute GVHD.
To our knowledge, this study documents for the first time the presence of activated APC, indicated by increased CD64 expression level in skin biopsies of patients with acute GVHD, although the number of evaluated patients is limited. More functional studies may open new avenues towards APC-directed treatment options.
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